Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals is a leading anti-diabetic pharmaceutical company in China (hereinafter referred to as Wanbang).It has been a sole subsidiary of Fosun Group who is the largest privately-owned conglomerate in China since 2004. Wanbang has been focusing at the development, manufacture and sale of pharmaceuticals to address the unmet medical needs in the area of diabetic disease since its establishment in 1981.

Currently, Wanbang control Shanghai Chemo Pharma, Wanbang Jinqiao Pharma, Hebei Fulin Pharma, Wanbang Pharmaceutical Marketing and Distribution Co., Ltd.

Wanbang is committed to providing medicines of safety and efficacy to improve the health and quality of life for patients of diabetes and related cardiovascular diseases. In order to enhance the availability and affordability of anti-diabetic products to patients, Wanbang has established a well trained and specialized marketing & sales team that covers the anti-diabetic markets all over China. It has established efficient long-term strategic cooperative relationships with domestic and worldwide distributors, responding rapidly to the customers' needs by providing effective and safe products to patients in a timely and effective way. Wanbang ranked No. 1 with four products in market share in China: Animal Insulin , Glimepiride Tablet, Meglumine Adenosine Cyclophosphate . Wanbang also have good performance in EPO, Bangtan(Telmisatan) and Heparin sodium.

Wanbang Value “Self-improvement, Teamwork Spirit, Performance, Social Responsibility”. We bear the responsibility and mission from society, promote the building of EHS, create a culture of army、school and family.

Wanbang has a sale net over the country, and builds Prescription, OTC, General Product District, and has more than one thousand salers.

Five year stratagem: Focus on the Diabetic Product, spread in cardiovascular and anti-tumour fields.

Our Mission: We promise a healthy life.
Vision: An internationally distinguished-diabetes company.